A patient diagnosed to have deep vein thrombosis is being treated with heparin. Which of the following test will you order to adjust its dosage :
**Core Concept**
The management of heparin in patients with deep vein thrombosis (DVT) requires monitoring to prevent both thrombosis and bleeding. Heparin exerts its anticoagulant effect by enhancing the activity of antithrombin III, which inhibits the conversion of prothrombin to thrombin.
**Why the Correct Answer is Right**
The activated partial thromboplastin time (aPTT) is the standard test used to monitor heparin therapy. Heparin increases the aPTT by prolonging the time it takes for blood to clot. By measuring aPTT, healthcare providers can adjust heparin dosages to maintain a therapeutic range, typically between 1.5 and 2.5 times the control value. This ensures effective anticoagulation while minimizing the risk of bleeding complications.
**Why Each Wrong Option is Incorrect**
**Option A:** Thrombin time (TT) is not a reliable test for monitoring heparin therapy, as it measures the time it takes for thrombin to convert fibrinogen to fibrin, which is not directly affected by heparin.
**Option B:** Prothrombin time (PT) is used to monitor warfarin therapy, not heparin.
**Option C:** Fibrin degradation products (FDPs) are markers of fibrinolysis, not heparin activity.
**Clinical Pearl / High-Yield Fact**
When monitoring heparin therapy, it's essential to use a standardized aPTT reagent and control to ensure accurate results.
**Correct Answer:** .